PPME1 and glioblastoma: Therefore, PME-1 expression could potentially serve as a marker to stratify GBM patients when testing oxidative therapies, or to stratify patients in non/semi/good-response groups for current standard therapies (radiotherapy and TMZ chemotherapy), which both induce oxidative stress as well [57].